Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a given patient. In order to expeditiously evaluate a targeted agent against a potential ‘driver’ genetic aberration, so-called Basket trials are conducted. Basket trials enroll patients with multiple tumor types that carry a common genetic aberration and evaluate a single targeted treatment regimen. I will discuss the rationale, design, and challenges in conducting Basket trials.
1. Learn about when to consider conducting a Basket trial and how to design it
2. Learn about the promises and challenges of identifying patients based on genomic aberrations